PURPOSE: Poorly water-soluble compounds are being found with increasing frequency among pharmacologically active new chemical entities, which is a major concern to the pharmaceutical industry. Some particle engineering technologies have been shown to enhance the dissolution of many promising new compounds that perform poorly in formulation and clinical studies (Rogers et. al., Drug Dev Ind Pharm 27:1003-1015). One novel technology, controlled precipitation, shows significant potential for enhancing the dissolution of poorly soluble compounds. In this study, controlled precipitation is introduced; and process variables, such as mixing zone temperature, are investigated. Finally, scale-up of controlled precipitation from milligram or gram to kilogram quantities is demonstrated. METHODS: Dissolution enhancement capabilities were established using two poorly water-soluble model drugs, danazol and naproxen. Stabilized drug particles from controlled precipitation were compared to milled, physical blend, and bulk drug controls using particle size analysis (Coulter), X-ray powder diffraction (XRD), scanning electron microscopy (SEM), dissolution testing (USP Apparatus 2), and residual solvent analysis. RESULTS: Stabilized nano- and microparticles were produced from controlled precipitation. XRD and SEM analyses confirmed that the drug particles were crystalline. Furthermore, the stabilized particles from controlled precipitation exhibited significantly enhanced dissolution properties. Residual solvent levels were below FDA limits. CONCLUSIONS: Controlled precipitation is a viable and scalable technology that can be used to enhance the dissolution of poorly water-soluble pharmaceutical compounds.
PURPOSE: Poorly water-soluble compounds are being found with increasing frequency among pharmacologically active new chemical entities, which is a major concern to the pharmaceutical industry. Some particle engineering technologies have been shown to enhance the dissolution of many promising new compounds that perform poorly in formulation and clinical studies (Rogers et. al., Drug Dev Ind Pharm 27:1003-1015). One novel technology, controlled precipitation, shows significant potential for enhancing the dissolution of poorly soluble compounds. In this study, controlled precipitation is introduced; and process variables, such as mixing zone temperature, are investigated. Finally, scale-up of controlled precipitation from milligram or gram to kilogram quantities is demonstrated. METHODS: Dissolution enhancement capabilities were established using two poorly water-soluble model drugs, danazol and naproxen. Stabilized drug particles from controlled precipitation were compared to milled, physical blend, and bulk drug controls using particle size analysis (Coulter), X-ray powder diffraction (XRD), scanning electron microscopy (SEM), dissolution testing (USP Apparatus 2), and residual solvent analysis. RESULTS: Stabilized nano- and microparticles were produced from controlled precipitation. XRD and SEM analyses confirmed that the drug particles were crystalline. Furthermore, the stabilized particles from controlled precipitation exhibited significantly enhanced dissolution properties. Residual solvent levels were below FDA limits. CONCLUSIONS: Controlled precipitation is a viable and scalable technology that can be used to enhance the dissolution of poorly water-soluble pharmaceutical compounds.
Authors: Xiaoxia Chen; Timothy J Young; Marazban Sarkari; Robert O Williams; Keith P Johnston Journal: Int J Pharm Date: 2002-08-21 Impact factor: 5.875
Authors: Marazban Sarkari; Judith Brown; Xiaoxia Chen; Steve Swinnea; Robert O Williams; Keith P Johnston Journal: Int J Pharm Date: 2002-08-28 Impact factor: 5.875
Authors: True L Rogers; Andrew C Nelsen; Jiahui Hu; Judith N Brown; Marazban Sarkari; Timothy J Young; Keith P Johnston; Robert O Williams Journal: Eur J Pharm Biopharm Date: 2002-11 Impact factor: 5.571
Authors: True L Rogers; Kirk A Overhoff; Parag Shah; Patricia Santiago; Miguel J Yacaman; Keith P Johnston; Robert O Williams Journal: Eur J Pharm Biopharm Date: 2003-03 Impact factor: 5.571
Authors: Michal E Matteucci; Joseph C Paguio; Maria A Miller; Robert O Williams Iii; Keith P Johnston Journal: Pharm Res Date: 2008-08-15 Impact factor: 4.200
Authors: Muhammad Umar Khayam Sahibzada; Abdul Sadiq; Hani S Faidah; Muhammad Khurram; Muhammad Usman Amin; Abdul Haseeb; Maria Kakar Journal: Drug Des Devel Ther Date: 2018-02-14 Impact factor: 4.162